Search clinical trials for: Denosumab (CP2)

Total 3080 results

Amgen

Completed

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

United States, Denmark, Poland, Canada
Amgen

Completed

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

Healthy Volunteer

United States
Bionos Biotech S.L.

Completed

Bioavailability of Different Collagen-based Treatments After Oral Intake

Healthy Volunteers

Spain
Turku University Hospital
Amgen

Completed

Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (ProliaHip)

Hip Osteoarthritis

Finland
Fudan University

Recruiting

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Breast Cancer

China
Amgen

Completed

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

Osteoporosis | Osteopenia | Low Bone Mineral Density | Low Bone Mass | Males With Osteoporosis
GlaxoSmithKline

Completed

A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Osteoporosis, Postmenopausal

Korea, Republic of
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

Poland
Borstkanker Onderzoek Groep
Amgen

Withdrawn

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer (PERIDENO)

Breast Neoplasms

Netherlands
Swiss Group for Clinical Cancer Research

Active, not recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

Switzerland, Germany, Austria
Luye Pharma Group Ltd.
Parexel

Completed

A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection

Healthy

Germany
GlaxoSmithKline

Completed

China HVT Safety, PK, PD

Osteoporosis

China
National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
National Institute of Dental and Craniofacial Research...

Recruiting

Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia

Fibrous Dysplasia

United States
Shanghai JMT-Bio Inc.

Completed

A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
GlaxoSmithKline

Completed

A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Osteoporosis, Postmenopausal

India
Amgen

Completed

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

Relapsed or Plateau-Phase Multiple Myeloma
Amgen

Completed

A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density

Osteoporosis | Osteopenia | Low Bone Mineral Density
Amgen

Completed

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Lymphoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Lung Cancer | Metastatic Cancer | Colon Cancer | Thyroid Cancer | Renal Cancer | Parathyroid Neoplasms | Endocrine Cancer | Hypercalcemia of Malignancy

United States, Italy, France, Canada, Poland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico
Indiana University

Withdrawn

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Vasculitis | Osteoporosis | Dermatomyositis | Juvenile Rheumatoid Arthritis | Glucocorticoid-induced Osteoporosis | Polyarthritis | Systemic Lupus Erythematosis

United States
HealthEast Care System
Amgen

Completed

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Osteoporosis | Bone Fracture

United States
Alvotech Swiss AG

Completed

AVT03 With Prolia in Healthy Male Subjects

Healthy Male Subjects

New Zealand
Nigde Omer Halisdemir University

Completed

Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients

Postmenopausal Osteoporosis

Turkey
Albert Einstein Healthcare Network
Amgen

Withdrawn

A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.

Osteoporosis
Rudolf Wuethrich

Completed

Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients (POSTOP)

Chronic Kidney Disease | Osteoporosis

Switzerland
Ole Lander Svendsen

Recruiting

The DENOCHARCOT Trial

Diabetes Mellitus | Charcot Foot

Denmark
NYU Langone Health

Completed

Presurgical Trial of Denosumab in Breast Cancer

Breast Cancer

United States
Shenzhen People's Hospital

Recruiting

Denosumab vs Zoledronate After Lumbar Fusion

Osteopenia | Lumbar Spondylolisthesis

China
Amgen

Completed

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France (PILOTE)

Post Menopausal Osteoporosis

France
Seoul National University Bundang Hospital

Unknown

Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial

Spine Deformity

Korea, Republic of
Qilu Pharmaceutical Co., Ltd.

Unknown

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Healthy People

China
Amgen

Completed

A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab

Osteoporosis | Postmenopausal Osteoporosis | Low Bone Mineral Density | Low Bone Mass
Shenzhen People's Hospital

Withdrawn

Denosumab and Screw Fixation for Osteoporotic Compression Fracture

Denosumab Allergy

China
Massachusetts General Hospital
Emory University; University of Rochester; Amgen; University Hospitals Cleveland...

Unknown

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Multiple Myeloma

United States
Peking University People's Hospital

Completed

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts (Deno-ABC)

Recurrent Disease | Pathological Fracture | Refractory Tumor | Bone Cyst Aneurysmal
Istituto Ortopedico Rizzoli

Completed

Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment (GCTLIMBS)

Giant Cell Tumor of Bone
Amgen

Completed

Denosumab Adherence Preference Satisfaction Study

Osteoporosis
Amgen

Completed

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Breast Cancer | Osteopenia | Low Bone Mineral Density
Mayo Clinic

Completed

Osteoclast Inhibition and Bone Formation

Aging | Bone Loss

United States
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Terminated

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

Spinal Cord Injury | Secondary Osteoporosis

United States
Hellenic Society for the Study of Bone Metabolism

Completed

Denosumab for the Treatment of Adult LCH

Langerhans Cell Histiocytosis

Greece
Qilu Pharmaceutical Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Healthy People

China
Kyoto Prefectural University of Medicine

Active, not recruiting

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Breast Cancer

Japan
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Postmenopausal Osteoporosis

China
Hans Mallmin

Completed

Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

Osteoarthritis, Hip | Ambulation Difficulty

Sweden
Shenzhen People's Hospital

Completed

Denosumab vs Zoledronate After Vertebroplasty

Denosumab Allergy | Zoledronic Acid Allergy

China
Capital Medical University

Recruiting

Denosumab Treatment in CKD Patients at High Risk of Fracture

Chronic Kidney Diseases | End Stage Renal Disease | Fracture | Bone Density, Low

China
Amgen

Withdrawn

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Solid Tumor | Metastatic Bone Disease
Lambda Therapeutic Research Ltd.
Intas Pharmaceutical Limited (Biopharma Division)

Recruiting

Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

Osteoporosis, Postmenopausal

India

Search clinical trials for: Denosumab (CP2)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations